论文部分内容阅读
Objective: We aimed to detect cytokeratin 19(CK19) and polymorphic epithelial mucin 1(MUC1) expression in peripheral blood of thyroid cancer patients, and investigate the clinical value of it as a diagnostic marker for circulating blood micrometastases. Methods: The flow cytometry(FCM) was used to detect and analyze CK19 and MUC1-expressing cells in peripheral blood of 491 thyroid cancer patients. Results: CK19 and MUC1 expression showed no statistically significant difference with gender and age in thyroid cancer patients(P > 0.05), while had statistically significant difference with tumor size, lymph node stage and distant metastasis(P < 0.01). The expression of CK19 and MUC1 were positively correlated(r = 0.628, P = 0.00). Conclusion: CK19 is closely related to MUC1 expression, tumor size, extent of invasion and distant metastasis in peripheral blood of thyroid cancer patients. The circulating blood CK19 and MUC1 tests can help predict thyroid cancer micrometastases and prognosis.
Objective: We aimed to detect cytokeratin 19 (CK19) and polymorphic epithelial mucin 1 (MUC1) expression in peripheral blood of thyroid cancer patients, and investigate the clinical value of it as a diagnostic marker for circulating blood micrometastases. Methods: The flow cytometry FCM) was used to detect and analyze CK19 and MUC1-expressing cells in peripheral blood of 491 thyroid cancer patients. Results: CK19 and MUC1 expression showed no dysfunction difference with gender and age in thyroid cancer patients (P> 0.05), while had were significant correlated with the tumor size, lymph node stage and distant metastasis (P <0.01). The expression of CK19 and MUC1 were positively correlated (r = 0.628, P = 0.00) , extent of invasion and distant metastasis in peripheral blood of thyroid cancer patients. The circulating blood CK19 and MUC1 tests can help predict thyroid cancer micrometastases and prognosis.